Next-generation ligandomics technology to globally map cellular ligands of the retina
Next-generation ligandomics technology to globally map cellular ligands of the retina
批准号:
10081460
负责人:
Hong Tian
金额:
$22.63万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-09-01 至 2023-02-28
关键词:
AddressAngiogenic FactorAntibody TherapyAutocrine CommunicationBindingBiomedical ResearchCell CommunicationCell membraneCell surfaceCellsCellular biologyComplexDNA sequencingDataDetectionDevelopmentDiabetes MellitusDiseaseDrug TargetingEndothelial CellsEndotheliumEventFDA approvedGenerationsHomeostasisHumanIndividualIntellectual PropertyLigand BindingLigandsLocationMapsMediatingMethodsMusOrganismParacrine CommunicationPathogenicityPharmaceutical PreparationsPhasePositioning AttributeProteinsProteomeProteomicsReportingResearchRetinaRoleRunningSafetySignal PathwaySignal TransductionSmall Business Innovation Research GrantSourceTechnologyTherapeuticTherapeutic InterventionTissuesTranscriptTransmembrane DomainVascular Endothelial CellVision researchautocrinebasecase-by-case basiscell typecomparativediabeticdrug discoverydrug qualityeffective interventionextracellularimprovedinnovationinnovative technologiesmouse modelneutralizing monoclonal antibodiesnew technologynext generationnovelnovel therapeuticsparacrineprotein expressionprotein profilingreceptorside effectsingle-cell RNA sequencingtargeted treatmenttherapeutic targettranscriptometranscriptomics
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Extracellular ligands are among the most valuable drug targets, but are much less exploited for disease therapy
than plasma membrane receptors. This is mainly because the technical hurdles for ligand discovery are much greater
than those for receptors, the latter of which can be conveniently identified based on their transmembrane domains.
Current omics technologies, such as proteomics, functional proteomics and transcriptomics, are not designed to
map extracellular ligands. Consequently, extracellular ligands are traditionally identified and characterized on a
case-by-case basis with inherent technical challenges. It is even more daunting to delineate ligands with
therapeutic potential. To address these challenges, we recently developed a unique platform technology of
ligandomics for global mapping of cell-wide ligands as well as disease-selective ligands in the absence of
receptor information. The validity and utility of this innovative technology has been demonstrated by efficient
discovery of highly disease-selective angiogenic factors and rapid development of novel anti-angiogenic
therapies with high efficacy and minimal side effects on normal vessels. However, this first-generation
ligandomics technology has the limited application only to homogeneous cells. In this project, we will develop
next-generation ligandomics technology that is applicable to any type of cells. In Aim 1, we will develop the next-
generation ligandomics technology to map ligand-secreting and binding cells connected through different ligand
signaling pathways. In Aim 2, we will apply the new technology to diabetic and healthy retina to systematically
identify diabetes-selective cellular ligands. The successful implementation of this project will markedly improve
the capacity of ligandomics to identify cellular ligands and disease-selective ligands for different cells. Our new
ligandomics technology developed in this project is universally applicable to any cells, tissues and diseases, and
therefore may have the potential to impact on a broad field of cell biology research and drug target discovery.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.drudis.2022.103430
发表时间:
2022-11
期刊:
Drug discovery today
影响因子:
7.4
作者:
[Prabuddha Waduge;H. Tian;K. Webster;Wei Li]
通讯作者:
Prabuddha Waduge;H. Tian;K. Webster;Wei Li
Optimal Efficacy and Safety of Humanized Anti-Scg3 Antibody to Alleviate Oxygen-Induced Retinopathy.
DOI:
10.3390/ijms23010350
发表时间:
2021-12-29
期刊:
International journal of molecular sciences
影响因子:
5.6
作者:
[He Y, Tian H, Dai C, Wen R, Li X, Webster KA, Li W]
通讯作者:
Li W
DOI:
10.3390/ijms22094809
发表时间:
2021-05-01
期刊:
International journal of molecular sciences
影响因子:
5.6
作者:
[Dai C, Webster KA, Bhatt A, Tian H, Su G, Li W]
通讯作者:
Li W
海外基金